Wednesday, April 23, 2025 Congratulations to the researchers who had poster presentations at the ASCO Genitourinary Cancer Symposium in San Francisco, February 13-15, 2025. PRC4 - Ryan CJ, Kim H, Morris MJ, Alyamani M, Diaz R, Beltran H, Armstrong AJ, Sharifi N, Halabi S. Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial. ASCO Genitourinary Cancer Symposium. Journal of Clinical Oncology 43 [5_suppl], 246-246. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.5_suppl.246 Morris MJ, Flynn J, Zhao B, Anand A, Sjöstrand K, Larson SM, Scher HI, Regazzi AM, Borzillo GV, Park A, Schwartz LH, Heller G. A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy. ASCO Genitourinary Cancer Symposium. Journal of Clinical Oncology 43 [5_suppl], 264-264. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.5_suppl.264 Chalker C, Ong M, McKay RR, Tangen C, Gulati S, Keim M, Lerner SP, Dorff TB, Sokolova A. Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America. ASCO Genitourinary Cancer Symposium. Journal of Clinical Oncology 43 [5_suppl], 263-263. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.5_suppl.263
